[The 46th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 49th Survey in 2023)].

Abstract

This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2023 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 971 institutions out of 1,181 to which the questionnaire had been sent. A total of 884,272 radiopharmaceutical administrations were reported. Fifteen cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.7. No case of defective products was reported.